Board of Directors Jerry McMahon, Ph.D. - Chairman and Chief Executive Officer Robert S. Basso - Director; Member, Audit Committee; Member, Compensation Committee Frederick B. Craves, Ph.D. - Director; Member, Nominating and Corporate Governance Committee E. Rolland Dickson, M.D. - Director; Chair, Nominating and Corporate Governance Committee; Member, Compensation Committee Carl S. Goldfischer, M.D. - Director Robert M. Littauer - Director; Chair, Audit Committee; Member, Compensation Committee Ronald A. Martell - President and Chief Operating Officer Nicholas J. Simon - Director; Chair, Compensation Committee David R. Stevens, DVM, Ph.D. - Director; Member, Nominating and Corporate Governance Committee; Member, Audit Committee Robert S. Basso Director Member, Audit Committee Member, Compensation Committee Robert S. Basso has been a director since 2007. He was previously executive vice president of Fidelity’s National Financial Services unit. He founded BEST Partners LLC, an independent consulting firm in 2006. He has nearly 40 years of experience in the financial services industry. Prior to his position as executive vice president of Fidelity's National Financial Services unit, following its acquisition of Correspondent Services Corporation (CSC), the UBS AG clearing subsidiary, Mr. Basso was president and chairman of CSC. Prior to that, he served as president of Broadcort Capital Corp., the Merrill Lynch & Co. clearing subsidiary, which he established and developed. Mr. Basso also was a managing director of PaineWebber, UBS and Merrill Lynch. He began his Wall Street career with Loeb, Rhoades & Company. Mr. Basso serves as an advisor to several independent entities. He is currently a trustee of the Securities Industry Foundation for Investor Education (SIFIE). He earned a B.S. degree from Seton Hall University and an M.B.A. from Pace University. Frederick B. Craves, Ph.D. Director Member, Nominating and Corporate Governance Committee Frederick Craves, Ph.D., served as vice chairman of the Board of Directors from March 2003 to May 2004, and Chairman of the Board from July 1992 to March 2003. Dr. Craves is the founder and Managing Director of Bay City Capital, where he also serves as chair of the Executive Committee and is a member of the Board of Directors. Before founding Bay City Capital, Dr. Craves spent over 20 years leading and managing biotechnology and pharmaceutical companies. Previously, he was Executive Vice President of Schering Berlin and Chief Executive Officer and President of Berlex Biosciences, a research, development and manufacturing organization. Dr. Craves was also the founding Chairman of the Board and Chief Executive Officer of Codon, and co-founder of Creative Biomolecules. He previously served as a director of Medarex, Inc. and Incyte Corporation. Dr. Craves is currently a member of the board of directors of BioSeek, Inc., Ponaird Pharmaceuticals and VIA Pharmaceuticals and is Vice Chairman of Reliant Pharmaceuticals. He also serves as a member of The J. David Gladstone Institute's Advisory Council and is a member of the Board of Trustees of Loyola Marymount University in Los Angeles. Dr. Craves earned a BS in Biology from Georgetown University and a PhD in Pharmacology and Toxicology from the University of California, San Francisco. E. Rolland Dickson, M.D. Director Chair, Nominating and Corporate Governance Committee Member, Compensation Committee Rolland Dickson, M.D., has been a director since May 1988. In December 2003, he retired as the Mary Lowell Leary Professor of Medicine at the Mayo Medical School and as director of development at the Mayo Foundation for Medical Education and Research, positions he had held since 1993. Dr. Dickson continues to hold emeritus titles for each of those positions. In 1999, he was appointed to the Board of Trustees of the Mayo Foundation. He is a member of the scientific advisory committees of Baxter International and BCC. He is also a director of Axcan Pharma Inc., a publicly owned biotechnology company, and Pathways Diagnostic Corporation, a development stage biotechnology company. He received his M.S. degree from the University of Minnesota and his M.D. degree from The Ohio State University. Carl S. Goldfischer, M.D. Director Carl S. Goldfischer, M.D., has been a director since 2000. He is a Managing Director of Bay City Capital and serves on its Board of Directors and Executive Committee. Dr. Goldfischer's background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Dr. Goldfischer was, until mid-2000, Chief Financial Officer of ImClone Systems where he oversaw financial operations and strategic planning. Previously, Dr. Goldfischer was a Research Analyst with the Reliance Insurance Company, helping to establish its portfolio and presence in the health care investment community. Dr. Goldfischer currently serves as Chairman of the Board of Syntonix Pharmaceuticals, and as a director for Avera Pharmaceuticals, BrainCells, Inc., EnteroMedics, Etex Corporation, MAP Pharmaceuticals, Metabolex, and PTC Therapeutics. Dr. Goldfischer is also a member of the Board of Trustees of Sarah Lawrence College. He received an MD with honors in Scientific Research from Albert Einstein College of Medicine, and a BA from Sarah Lawrence College. Robert M. Littauer Director Chair, Audit Committee Member, Compensation Committee Robert Littauer has been a director since May 2004. He has more than 30 years of experience in the medical technology, high technology and biotechnology industries. From June 1987 to September 1996 he served the company in various management positions, including senior vice president, chief financial officer and treasurer. Mr. Littauer has been chief executive officer of Light Sciences Oncology, Inc., an early-stage biotechnology company, since October 2005. He has been a partner of Tatum Partners, a professional services firm, since September 2003. Mr. Littauer was chief executive officer of Kaleidos Pharma, Inc., an early-stage biotechnology company, from July 2002 to December 2005. Previously, he served as vice president and chief financial officer of Detto Technologies, Inc., a software developer, from June 2001 to July 2002. He was chief executive officer from January 2001 to April 2001, and vice president and chief financial officer from October 2000 to January 2001 at Plymedia, Inc., a developer of digital imaging technology. Prior to that, he held chief financial officer and senior executive positions at Avenue A, Inc. (now aQuantive, Inc.), an internet media company, and at Ostex International, Inc., a medical diagnostics company. Mr. Littauer received an M.B.A. degree and B.S. degree in Industrial Engineering and Operations from Cornell University. Nicholas J. Simon Director Chair, Compensation Committee Nicholas J. Simon joined the Board of Directors in April 2006. He has been a managing director of Clarus Ventures, Inc., LLC, a life sciences focused venture capital firm that he co-founded in 2005. He has served as a general partner of MPM BioVentures III since October 2001. He has more than 26 years of industry and investment experience in biotechnology. From 2000 to July 2001, he was chief executive officer, founder and a director of Collabra Pharma, Inc., a pharmaceutical development company. From 1989 to 2000, Mr. Simon served in various management positions at Genentech, Inc., including vice president of business and corporate development. Mr. Simon currently serves on the boards of directors of Barrier Therapeutics, Inc. and CoTherix, Inc., both public biotechnology companies. In addition, he is a director of ARYx Therapeutics, Inc., NeoSil Incorporated, QuatRx Pharmaceuticals Co. and Verus Pharmaceuticals, Inc., which are private biotechnology companies. He also is on the advisory council at the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California San Francisco. Mr. Simon received a B.S. degree in microbiology from the University of Maryland and an M.B.A. in marketing from Loyola University. David R. Stevens, DVM, Ph.D. Director Member, Nominating and Corporate Governance Committee Member, Audit Committee Dr. Stevens has worked in the pharmaceutical and biotechnology industries since 1978. He is currently Executive Chairman of CanCogTechologies, Inc., a contract research organization and a board member of Poniard Pharmaceuticals, Inc., (cancer therapy) Micro-Imaging Solutions, LLC., and Advanced Headache Intervention, both medical device companies, and Aqua Bounty Technologies, Inc., a biotechnology firm. He was an advisor to Bay City Capital LLC from 1999-2006. Dr. Stevens was President and CEO of Deprenyl Animal Health, Inc., a veterinary pharmaceutical company, from 1990 to 1998, and Vice President, Research and Development, of Agrion Corp., a biotechnology company, from 1985 to 1988. He began his career in pharmaceutical research and development at the former Upjohn Company, where he contributed to the preclinical evaluation of Xanax and Halcion. Dr. Stevens received BS and DVM degrees from Washington State University, and a PhD in Comparative Pathology from the University of California, Davis. He is a Diplomate of the American College of Veterinary Pathologists.